Reply by Authors

Ozgur raises some relevant points regarding diabetes stratification, metformin treatment duration and hyperlipidemia evaluation. It is correct that due to the information available in the Ontario Diabetes Database through the Institute for Clinical Evaluative Sciences we were unable to separate patients into type 1 and type 2 diabetes groups. However, we excluded insulin users due to the greater amount of comorbidities associated with more severe diabetes and the evidence indicating that higher levels of insulin can contribute to prostate cancer progression and worse outcomes.
Source: The Journal of Urology - Category: Urology & Nephrology Tags: Letter to the Editor/Errata Source Type: research